AI Drug Firm Raises $5bn to Push Candidates

Isomorphic Labs, a DeepMind spinout, plans to advance AI-designed cancer and immune treatments toward clinical trials; the candidates remain pre-clinical.

Updated on Nov. 17, 2026 in Biotech

Isometric editorial illustration of a folded protein built from stacked matte spheres and rods on a cream plinth, evoking AI-driven drug design.
Isomorphic Labs, the Google DeepMind spinout, raised $5bn in a Series C round co-led by Greenoaks and Sequoia to advance AI-designed cancer and immune candidates toward clinical trials. AI Illustration. Upload story photo >

Live Poll

Do you trust AI to help develop safe new medicines?

Isomorphic Labs raised a $5bn Series C funding round, co-led by Greenoaks and Sequoia, with participation from Andreessen Horowitz, Thrive Capital, Alphabet, Alphabet's GV and CapitalG, Tamesek, and the Sovereign AI fund. The round follows a $2.1bn Series B raised six months earlier. This is a financing announcement; the drug candidates it funds remain at the research and pre-clinical stage.

Why it matters

The company, spun out of Google DeepMind and founded by Demis Hassabis, is betting that AI-driven drug design can move from software to clinical candidates. The capital raised in six months signals investor conviction that AI-designed therapeutics are approaching the point of human trials.

The company reports the scale of its capital base, with a $5bn Series C following a $2.1bn Series B. No benchmark or clinical performance figure for IsoDDE, its proprietary drug design engine, is provided in the source, so the financing cannot be translated into demonstrated drug-design capability.

The players

Isomorphic Labs

A drug discovery company spun out of Google DeepMind, building AI drug design tools on AlphaFold-derived software.

Demis Hassabis

The founder of Isomorphic Labs and a leading AI researcher who led Google DeepMind.

Greenoaks

A venture capital firm that co-led the $5bn Series C round.

Sequoia

A venture capital firm that co-led the $5bn Series C round.

The details

Isomorphic Labs builds on software developed at DeepMind, including AlphaFold, a system that predicts protein structures, which are the three-dimensional shapes that determine how a molecule interacts with disease targets. The company is scaling IsoDDE, its proprietary drug design engine, alongside a pipeline of AI-designed therapeutic candidates. Its research focuses on cancer and immune disorders, and it is building a partner ecosystem to study mechanistic disease biology, meaning how diseases arise at the molecular level.

Timeline

  1. Series B round of $2.1bn raised six months before the Series C.

  2. Series C round of $5bn announced on November 17, 2026.

The Tech Race

The round positions Isomorphic Labs as a commercial successor to AlphaFold, the protein structure system from its parent DeepMind. Its ambition to take AI-designed candidates into clinical trials places it in a race to show that computational drug design can produce medicines, not just predictions.

The round does not change any available treatment; the company's candidates remain pre-clinical and no launch date is announced. Patients would see a difference only after candidates clear clinical trials, a process whose timing the source does not give.

The takeaway

The key trajectory is whether AI-designed candidates can enter clinical trials, the milestone the company says this capital will support. Watch for the first clinical trial announcement from Isomorphic Labs as the test of whether this funding converts into medicines.

Further reading

For the broader field, explore recent Biotech coverage of AI-driven drug discovery.

Live Poll

Do you trust AI to help develop safe new medicines?